Adenosine deaminase enhances T-cell response elicited by dendritic cells loaded with inactivated HIV

Immunology and Cell Biology

Volumn 87, Issue 8, 2009, Pages 634-639

  Climent, Núria ^a,b   Martinez Navio, José M ^c   Gil, Cristina ^b   Garcia, Felipe ^b   Rovira, Cristina ^b   Hurtado, Carmen ^b   Miralles, Laia ^b   Gatell, José M ^b   Gallart, Teresa ^a,b   Mallol, Josefa ^c   Lluis, Carme ^c   Franco, Rafael ^c  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Adenosine deaminase; Anti HIV response; Cytokines as vaccine adjuvant; Dendritic cells; T cell proliferation

Indexed keywords

ADENOSINE DEAMINASE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADJUVANT THERAPY; ADULT; ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; FEMALE; HELPER CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE RESPONSE; LYMPHOCYTE PROLIFERATION; MALE; MONOCYTE; PHENOTYPE; T LYMPHOCYTE; VIRUS INACTIVATION;

ADENOSINE DEAMINASE; ADULT; CELL PROLIFERATION; COCULTURE TECHNIQUES; CYTOKINES; DENDRITIC CELLS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; T-LYMPHOCYTES; VIRAL LOAD; VIRUS INACTIVATION;

EID: 70450265488     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2009.53     Document Type: Article

References (55)

1. Joint United Nations Programme on HIV/AIDS AIDS epidemic update 2007 (http:// data.unaids.org/pub/EPISlides/2007/2007-epiupdate-en.pdf). Retrieved on 2007-11-19.
2. Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, Weiss RA. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 1984; 312: 763-767.
3. Klatzmann D, Barre-Sinoussi F, Nugeyre MT, Danquet C, Vilmer E, Griscelli C et al. Selective tropism of lymphadenopathy associated virus (LAV) for helper-inducer T lymphocytes. Science 1984; 225: 59-63. (Pubitemid 14123409)
4. Pantaleo G, Fauci AS. Immunopathogenesis of HIV infection. Annu Rev Microbiol 1996; 50: 825-854.
5. Garcia F, Plana M, Vidal C, Cruceta A, O'Brien WA, Pantaleo G et al. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. AIDS 1999; 13: F79-F86.
6. Saksena NK, Haddad DN. Viral reservoirs an impediment to HAART: New strategies to eliminate HIV-1. Curr Drug Targets Infect Disord 2003; 3: 179-206.
7. Autran B, Carcelain G, Combadiere B, Debre P. Therapeutic vaccines for chronic infections. Science 2004; 305: 205-208.
8. Lu W, Arraes LC, Ferreira WT, Andrieu JM. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med 2004; 10: 1359-1365.
9. Garcia F, Lejeune M, Climent N, Gil C, Alcamí J, Morente V et al. Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection. J Infect Dis 2005; 191: 1680-1685.
10. Connolly NC, Colleton BA, Rinaldo CR. Treating HIV-1 infection with dendritic cells. Curr Opin Mol Ther 2007; 9: 353-363.
11. Connolly NC, Whiteside TL, Wilson C, Kondragunta V, Rinaldo CR, Riddler SA. Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide- loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals. Clin Vaccine Immunol 2008; 15: 284-292.
12. Morrow MP, Weiner DB. Cytokines as adjuvants for improving anti-HIV responses. AIDS 2008; 22: 333-338.
13. Franco R, Pacheco R, Gatell JM, Gallart T, Lluis C. Enzymatic and extraenzymatic role of adenosine deaminase 1 in T-cell-dendritic cell contacts and in alterations of the immune function. Crit Rev Immunol 2007; 27: 495-509.
14. Pacheco R, Martinez-Navio JM, Lejeune M, Climent N, Oliva H, Gatell JM et al. CD26, adenosine deaminase, and adenosine receptors mediate costimulatory signals in the immunological synapse. Proc Natl Acad Sci USA 2005; 102: 9583-9588.
15. Foley P, Kazazi F, Biti R, Sorrell TC, Cunningham AL. HIV infection of monocytes inhibits the T-lymphocyte proliferative response to recall antigens, via production of eicosanoids. Immunology 1992; 75: 391-397.
16. Veiga AP, Casseb J, Duarte AJ. Humoral response to hepatitis B vaccination and its relationship with T CD45RA+ (naive) and CD45RO+ (memory) subsets in HIV-1- infected subjects. Vaccine 2006; 24: 7124-7128.
17. Opravil M, Fierz W, Matter L, Blaser J, Luthy R. Poor antibody response after tetanus and pneumococcal vaccination in immunocompromised, HIV-infected patients. Clin Exp Immunol 1991; 84: 185-189.
18. Boasso A, Shearer GM. Chronic innate immune activation as a cause of HIV-1 immunopathogenesis. Clin Immunol 2008; 126: 235-242.
19. Hunt PW. Role of immune activation in HIV pathogenesis. Curr HIV AIDS Rep 2007; 4: 42-47.
20. Liu Z, Cumberland WG, Hultin LE, Kaplan AH, Detels R, Giorgi JV. CD8+ T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18: 332-340.
21. Kestens L, Vanham G, Vereecken C, Vandenbruaene M, Vercauteren G, Colebunders RL et al. Selective increase of activation antigens HLA-DR and CD38 on CD4+ CD45RO+ T lymphocytes during HIV-1 infection. Clin Exp Immunol 1994; 95: 436-441.
22. Sousa AE, Carneiro J, Meier-Schellersheim M, Grossman Z, Victorino RM. CD4T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV- but only indirectly to the viral load. J Immunol 2002; 169: 3400-3406.
23. Gruters RA, Terpstra FG, De Jong R, Van Noesel CJ, Van Lier RA, Miedema F. Selective loss of T cell functions in different stages of HIV infection Early loss of anti-CD 3- induced T Fpage: Cell proliferation followed by decreased anti-CD3-induced cytotoxic T lymphocyte generation in AIDS-related complex and AIDS. Eur J Immunol 1990; 20: 1039-1044.
24. Sieg SF, Harding CV, Lederman MM. HIV-1 infection impairs cell cycle progression of CD4(+) T cells without affecting early activation responses. J Clin Invest 2001; 108: 757-764.
25. Pahwa R, McCloskey TW, Aroniadis OC, Strbo N, Krishnan S, Pahwa S. CD8+ T cells in HIV disease exhibit cytokine receptor perturbation and poor T cell receptor activation but are responsive to gamma-chain cytokine-driven proliferation. J Infect Dis 2006; 193: 879-887.
26. Pedersen C, Dickmeiss E, Gaub J, Ryder LP, Platz P, Lindhardt BO et al. T-cell subset al.terations and lymphocyte responsiveness to mitogens and antigen during severe primary infection with HIV: A case series of seven consecutive HIV seroconverters. AIDS 1990; 4: 523-526.
27. Schellekens PT, Roos MT, De Wolf F, Lange JM, Miedema F. Low T-cell responsiveness to activation via CD3/TCR is a prognostic marker for acquired immunodeficiency syndrome (AIDS) in human immunodeficiency virus-1 (HIV-1)-infected men. J Clin Immunol 1990; 10: 121-127.
28. Galati D, Bocchino M. New insights on the perturbations of T cell cycle during HIV infection. Curr Med Chem 2007; 14: 1920-1924.
29. Piedimonte G, Corsi D, Paiardini M, Cannavò G, Ientile R, Picerno I et al. Unscheduled cyclin B expression and p34 cdc2 activation in T lymphocytes from HIV-infected patients. AIDS 1999; 13: 1159-1164.
30. Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 2002; 20: 621-667.
31. Sutherland R, Yang H, Scriba TJ, Ondondo B, Robinson N, Conlon C et al. Impaired IFN-gamma-secreting capacity in mycobacterial antigen-specific CD4T cells during chronic HIV-1 infection despite long-term HAART. AIDS 2006; 20: 821-829.
32. Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996; 4: 25-36.
33. Wong GH, Krowka JF, Stites DP, Goeddel DV. In vitro anti-human immunodeficiency virus activities of tumor necrosis factor-alpha and interferon-gamma. J Immunol 1988; 140: 120-124.
34. Ahlers JD, Belyakov IM, Matsui S, Berzofsky JA. Mechanisms of cytokine synergy essential for vaccine protection against viral challenge. Int Immunol 2001; 13: 897-908.
35. Ahlers JD, Dunlop N, Alling DW, Nara PL, Berzofsky JA. Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: Granulocyte-macrophage colony-stimulating factor and TNF-alpha synergize with IL-12 to enhance induction of cytotoxic T lymphocytes. J Immunol 1997; 158: 3947-3958.
36. Kato K, Takaue Y, Wakasugi H. T-cell-conditioned medium efficiently induces the maturation and function of human dendritic cells. J Leukoc Biol 2001; 70: 941-949. (Pubitemid 33151133)
37. Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and gp130. Blood 1995; 86: 1243-1254.
38. Poli G, Bressler P, Kinter A et al. Interleukin 6 induces human immunodeficiency virus expression in infected monocytic cells alone and in synergy with tumor necrosis factor alpha by transcriptional and post-transcriptional mechanisms. J Exp Med 1990; 172: 151-158.
39. Jiang W, Jin N, Cui S, Li Z, Zhang L, Wang H et al. Enhancing immune responses against HIV-1 DNA vaccine by coinoculating IL-6 expression vector. J Virol Methods 2006; 136: 1-7.
40. Kidd P. Th1/Th2 balance: The hypothesis, its limitations, and implications for health and disease. Altern Med Rev 2003; 8: 223-246.
41. Gor DO, Rose NR, Greenspan NS. TH1-TH2: A procrustean paradigm. Nat Immunol 2003; 4: 503-505.
42. Clerici M, Shearer GM. A TH1-TH2 switch is a critical step in the etiology of HIV infection. Immunol Today 1993; 14: 107-111.
43. Foulds KE, Wu CY, Seder RA. Th1 memory: Implications for vaccine development. Immunol Rev 2006; 211: 58-66.
44. Connolly NC, Riddler SA, Rinaldo CR. Proinflammatory cytokines in HIV disease-a review and rationale for new therapeutic approaches. AIDS Rev 2005; 7: 168-180.
45. Kulkosky J, Culnan DM, Roman J, Dornadula G, Schnell M, Boyd MR et al. Prostratin: Activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood 2001; 98: 3006-3015.
46. Barouch DH, Letvin NL, Seder RA. The role of cytokine DNAs as vaccine adjuvants for optimizing cellular immune responses. Immunol Rev 2004; 202: 266-274.
47. Gartner S, Markovits P, Markovitz DM, Kaplan MH, Gallo RC, Popovic M. The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 1986; 233: 215-219.
48. National Institute of Allergy and Infectious Diseases, Division of AIDS. DAIDS Virology Manual for HIV Laboratories,. Health and Human Services: Washington, DC, 1997.
49. Rossio JL, Esser MT, Suryanarayana K, Schneider DK, Bess Jr JW, Vasquez GM et al. Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J Virol 1998; 72: 7992-8001.
50. Poon B, Hsu JF, Gudeman V, Chen IS, Grovit-Ferbas K. Formaldehyde- treated, heatinactivated virions with increased human immunodeficiency virus type 1 env can be used to induce high-titer neutralizing antibody responses. J Virol 2005; 79: 10210-10217.
51. Boyum A. Isolation of leucocytes from human blood. Further observations. Methylcellulose, dextran, and ficoll as erythrocyteaggregating agents. Scand J Clin Lab Invest Suppl 1968; 97: 31-50.
52. Boyum A. Isolation of lymphocytes, granulocytes and macrophages. Scand J Immunol 1976; 5: 9-15.
53. Chougnet C, Cohen SS, Kawamura T, Landay AL, Kessler HA, Thomas E et al. Normal immune function of monocyte-derived dendritic cells from HIV-infected individuals: Implications for immunotherapy. J Immunol 1999; 163: 1666-1673.
54. Sapp M, Engelmayer J, Larsson M, Granelli-Piperno A, Steinman R, Bhardwaj N. Dendritic cells generated from blood monocytes of HIV-1 patients are not infected and act as competent antigen presenting cells eliciting potent T-cell responses. Immunol Lett 1999; 66: 121-128.
55. Franco R, Canela EI, Bozal J. Heterogeneous localization of some purine enzymes in subcellular fractions of rat brain and cerebellum. Neurochem Res 1986; 11: 423-435.